The Java-based Bayesian decision support tool for warfarin dosing performed comparably to NONMEM, with no differences in a priori predictions and a mean prediction error of -0.104 mg for a posteriori dose predictions.
Does a Java-based Bayesian decision support tool accurately predict individualized warfarin doses compared to NONMEM?
A newly developed Java-based Bayesian decision support tool provides accurate a priori and a posteriori warfarin dose predictions comparable to NONMEM, offering a more accessible platform for clinical dose individualization.
Mean Difference: -0.104
BACKGROUND: Warfarin is the most widely prescribed anticoagulant for the prevention and treatment of thromboembolic events. Although highly effective, the use of warfarin is limited by a narrow therapeutic range combined with a more than ten-fold difference in the dose required for adequate anticoagulation in adults. An optimal dose that leads to a favourable balance between the wanted antithrombotic effect and the risk of bleeding as measured by the prothrombin time International Normalised Ratio (INR) must be found for each patient. A model describing the time-course of the INR response can be used to aid dose selection before starting therapy (a priori dose prediction) and after therapy has been initiated (a posteriori dose revision). RESULTS: In this paper we describe a warfarin decision support tool. It was transferred from a population PKPD-model for warfarin developed in NONMEM to a platform independent tool written in Java. The tool proved capable of solving a system of differential equations that represent the pharmacokinetics and pharmacodynamics of warfarin with a performance comparable to NONMEM. To estimate an a priori dose the user enters information on body weight, age, baseline and target INR, and optionally CYP2C9 and VKORC1 genotype. By adding information about previous doses and INR observations, the tool will suggest a new dose a posteriori through Bayesian forecasting. Results are displayed as the predicted dose per day and per week, and graphically as the predicted INR curve. The tool can also be used to predict INR following any given dose regimen, e.g. a fixed or an individualized loading-dose regimen. CONCLUSIONS: We believe that this type of mechanism-based decision support tool could be useful for initiating and maintaining warfarin therapy in the clinic. It will ensure more consistent dose adjustment practices between prescribers, and provide efficient and truly individualized warfarin dosing in both children and adults.
Hamberg et al. (Fri,) conducted a other in Anticoagulation (n=49). Java-based Bayesian decision support tool vs. NONMEM was evaluated on A posteriori maintenance dose predictions (Mean prediction error -0.104 mg). The Java-based Bayesian decision support tool for warfarin dosing performed comparably to NONMEM, with no differences in a priori predictions and a mean prediction error of -0.104 mg for a posteriori dose predictions.